Get the Stockscreener App
7.15
33.40%
1.79
After Hours:
7.08
-0.07
-0.98%
Ataibeckley Inc stock is traded at $7.15, with a volume of 165.66M.
It is up +33.40% in the last 24 hours and up +72.71% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$5.36
Open:
$7.065
24h Volume:
165.66M
Relative Volume:
16.59
Market Cap:
$2.63B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
-3.1938
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
+34.15%
1M Performance:
+72.71%
6M Performance:
+96.43%
1Y Performance:
+164.81%
1-Day Range:
$7.02
$7.22
1-Week Range:
$4.81
$7.22
52-Week Range:
$2.67
$7.22
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
7.15 | 1.97B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 121.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 69.66B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.99B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 39.21B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.27B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Lilly to buy psychedelic-drug firm AtaiBeckley - Chemical & Engineering News
Nasdaq slides as chip selloff drags Wall Street lower - Proactive financial news
Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal - TradingView
AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout - TradingView
Lilly offers up to $3.8 billion for AtaiBeckley in bet on toad-derived ‘God molecule’ - drugdiscoverytrends.com
Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI) - Morningstar
AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline - Seeking Alpha
Eli Lilly Acquires Psychedelics Specialist AtaiBeckleyWhat Investors Should Know (LLY) - Seeking Alpha
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug - 24/7 Wall St.
Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition - MedCity News
Pharma giant Eli Lilly enters psychedelics space with AtaiBeckley takeover - Mugglehead Investment Magazine
Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion - marketscreener.com
ATAI Downgraded by Needham -- Rating Changed to Hold - GuruFocus
Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition - International Business Times
Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock - Barchart.com
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover - Pharmaceutical Technology
Lilly acquiring firm developing psychedelic depression treatments for up to $3.8M - Inside INdiana Business
Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn - The Times
Latham & Watkins Represents AtaiBeckley in Sale to Lilly - Latham & Watkins LLP
AtaiBeckley (ATAI) Sees 32.9% Surge in Stock Price - GuruFocus
Why Is GH Research Stock Trading Higher on Thursday? - Benzinga
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics - BioPharma Dive
Shareholder Alert: Ademi LLP investigates whether AtaiBeckley Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker - Advisor Perspectives
Eli Lilly agrees to $3.8B psychedelic buy - Axios
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion - Yahoo Finance Singapore
Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders - GlobeNewswire
AtaiBeckley Inc (ATAI:UW): Stock Price, Quote and News - BNN Bloomberg
Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion - qz.com
Lilly enters psychedelic drug race with up to US$3.8 billion AtaiBeckley deal - BNN Bloomberg
Eli Lilly deal to buy AtaiBeckley boosts psychedelic stocks - Seeking Alpha
Eli Lilly Acquires AtaiBeckley for $3.8B - AllSci
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - KELO-AM
Lilly confirms arrival of new psychedelic age with $3.8 billion AtaiBeckley buy - The Pharma Letter
AtaiBeckley (ATAI) Surges Over 31% to Reach $7.05 - GuruFocus
AtaiBeckley (NASDAQ: ATAI) stock jumps on Lilly deal as market discounts milestones - TechStock²
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion - Pharmaceutical Executive
Eli Lilly and Company entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. from Apeiron Investment Group Limited and others. - marketscreener.com
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday - Benzinga
Eli Lilly rises after AtaiBeckley purchase deal, RBC supportive - marketscreener.com
Eli Lilly to acquire AtaiBeckley to bolster its mental health push - marketscreener.com
How Lilly's AtaiBeckley Deal Accelerates Psychedelic Drug Commercialization Push - Pharmaceutical Commerce
Lilly To Acquire AtaiBeckley In $2.8 Billion Deal - Pulse 2.0
ATAI Stock Soars on Reports of Potential Acquisition by Eli Lilly - Yahoo Finance UK
LLY: Eli Lilly Acquires AtaiBeckley for $2.8 Billion in Psychede - GuruFocus
AtaiBeckley Stock Is Soaring 31% as Eli Lilly Agrees to Buy Psychedelic Drugmaker - Barron's
Eli Lilly (LLY) to Acquire AtaiBeckley in $2.8 Billion Deal - GuruFocus
Eli Lilly to acquire AtaiBeckley in deal worth up to $3.8 billion - MLex
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether AtaiBeckley Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
Stock Market Today: Dow Futures Rise, S&P 500 Falls As Trump Says Iran Wants To Negotiate— AtaiBeckley, J - Benzinga
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ataibeckley Inc Stock (ATAI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HERSHBERG ROBERT | Director |
Jul 07 '26 |
Sale |
4.96 |
100,000 |
496,000 |
100,000 |
1.36%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):